Showing results (71-80 of 100) with videos related to
Sort By:
Pageof 10
JCO Oncology Practice|August 2, 2021
Cancer Care in the Wake of a Cyberattack: How to Prepare and What to ExpectSteven Ades, Diego Adrianzen Herrera, Tim Lahey, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2023
AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast CancerSara M Tolaney, Arlene Chan, Katarina Petrakova, et al.Cancer|June 8, 2013
Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831Alvaro Moreno-Aspitia, David W Hillman, Stephen H Dyar, et al.CA: a Cancer Journal for Clinicians|February 19, 2020
Enhancing global access to cancer medicinesJavier Cortes, Jose Manuel Perez-García, Antonio Llombart-Cussac, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2017
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine TherapyGeorge W Sledge, Masakazu Toi, Patrick Neven, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2021
MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR<sup>+</sup>, HER2<sup>-</sup>-Advanced Breast CancerPatrick Neven, Stephen R D Johnston, Masakazu Toi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 8, 2013
Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trialEdith A Perez, Amylou C Dueck, Ann E McCullough, et al.JAMA Oncology|September 30, 2019
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical TrialGeorge W Sledge, Masakazu Toi, Patrick Neven, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 6, 2008
Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trialEdith A Perez, Vera J Suman, Nancy E Davidson, et al.Breast Cancer Research : BCR|April 30, 2013
Microwave imaging for neoadjuvant chemotherapy monitoring: initial clinical experiencePaul M Meaney, Peter A Kaufman, Lori S Muffly, et al.Pageof 10